Abstract:AIM:Many studies reveal an association between the acquired chemoresistant phenotype of cancer cells and tumor-initiating cell-like properties. The aim of this study was to determine the impact of c-Jun N-terminal kinase (JNK) on the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.METHODS:Two well-established human acquired chemoresistant cancer cell lines K562/A02 and KB/VCR, as well as their respective parental counterparts K562 and KB were tested. The expression of relevant mRNAs and proteins was detected using qRT-PCR and Western blotting, respectively. Sphere formation and self-renewal assays were used to study the tumor-initiating cell-like properties. Soft agar and colony formation assays were used to investigate tumorigenic ability.RESULTS:We observed that suppressing JNK activity by its specific small molecule inhibitor SP600125 or by limiting JNK1/2 expression with JNK1/2 shRNA lentiviruses inhibited the expression of pluripotent stem cell markers such as Oct4, Sox2, and Nanog in KB/VCR cells and K562/A02 cells as well as sphere formation and self-renewal abilities of K562/A02 cells. Additionally, inhibition of JNK activity significantly inhibited the in vitro and in vivo tumor-initiating abilities of KB/VCR cells. Furthermore, our data suggest that blocking JNK activity abundantly inhibited the Hedgehog (Hh) pathway activity, as reflected by reduction of Hedgehog (Hh) pathway target genes Gli1 and ptch1 at the mRNA level as well as Gli-luciferase activity.CONCLUSION:JNK maintains the tumor-initiating cell-like properties of acquired chemoresistant K562/A02 and KB/VCR cells potentially through activating the Hedgehog pathway. Thus, disruption of tumor-initiating cell-like properties by targeting JNK may be a new approach to combating acquired chemoresistance.

JNK signaling in cancer cell survival

Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival

THE CELL SURVIVAL FUNCTION OF JNK

MAPK/JNK Signalling: a Potential Autophagy Regulation Pathway

MAPK/JNK signaling: A potential autophagy regulation pathway.

Selective Inhibitors for JNK Signalling: a Potential Targeted Therapy in Cancer

Sustained C-Jun-nh2-kinase Activity Promotes Epithelial-Mesenchymal Transition, Invasion, and Survival of Breast Cancer Cells by Regulating Extracellular Signal-Regulated Kinase Activation.

c-Jun N-terminal kinase signaling in cellular senescence

JNK is Required for Maintaining the Tumor-Initiating Cell-Like Properties of Acquired Chemoresistant Human Cancer Cells.

The Role of JNK in Prostate Cancer Progression and Therapeutic Strategies

Targeting JNK kinase inhibitors via molecular docking: A promising strategy to address tumorigenesis and drug resistance

p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents.

JNK signaling in apoptosis

JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species

JNK2 Downregulation Promotes Tumorigenesis and Chemoresistance by Decreasing P53 Stability in Bladder Cancer

Signal integration by JNK and p38 MAPK pathways in cancer development

Nuclear JAK2: Form and Function in Cancer

JNK MAPK Regulates IFN-Stimulated Genes and Cell Adhesion in Chemoresistant, Quiescent Leukemic Cells

The Jun N-terminal kinases signaling pathway plays a “seesaw” role in ovarian carcinoma: a molecular aspect

JNK Pathway in Osteosarcoma: Pathogenesis and Therapeutics

The Pivotal Role of C-Jun Nh2-Terminal Kinase-Mediated Beclin 1 Expression During Anticancer Agents-Induced Autophagy in Cancer Cells